Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 94

Sort by

Sort Order Select

Journal Articles

Attrition after Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Products in Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 3794.

https://doi.org/10.1182/blood-2023-187583

Published: 2023

Journal Articles

Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 2215.

https://doi.org/10.1182/blood-2023-173040

Published: 2023

Journal Articles

Single Cell Multi-Omic Analysis of Tumor Microenvironment Evolution across the Disease Spectrum of Multiple Myeloma Identifies Differential Mechanisms of Immune Suppression

Minghao Dang, Hima Bansal, Maria Jose Acevedo-Calado, Li Qin, Wei Tan, Luz Yurany Moreno Moreno Rueda, Mei Huang, David Berrios Nolasco, Hans C. Lee, Krina K. Patel, Pei Lin, Sheeba K. Thomas, Donna M. Weber, Linghua Wang, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 89.

https://doi.org/10.1182/blood-2023-182902

Published: 2023

Journal Articles

Safety and Efficacy Outcomes for Patients with High-Risk Multiple Myeloma Receiving Idecabtagene Vicleucel: The MD Anderson Experience

Oren Pasvolsky, Michelle Hildebrandt, Naveen Subramanian, Christopher Ferreri, Hans C. Lee, Elisabet E. Manasanch, Sheeba K. Thomas, Donna M. Weber, Mahmoud Gaballa, Christen Dillard, Melody Becnel, Chitra Hosing, Pei Lin, Behrang Amini, Muzaffar H. Qazilbash, Nilesh Kalariya, Robert Z. Orlowski, Krina K. Patel

Blood (2023) 142 (Supplement 1): 4712.

https://doi.org/10.1182/blood-2023-187854

Published: 2023

Journal Articles

Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center

Blood (2023) 142 (Supplement 1): 4962.

https://doi.org/10.1182/blood-2023-174479

Published: 2023

Journal Articles

Lysosomal Associated Membrane Protein Family Member 5 (LAMP5) As a Novel Mediator of, and Target in High Risk Multiple Myeloma (MM)

Hua Wang, Luz Yurany Moreno Rueda, Minghao Dang, Luz Yurany Moreno Rueda, Hans C. Lee, Krina K. Patel, Sheeba K. Thomas, Donna M. Weber, Elisabet E. Manasanch, David E. Symer, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 873.

https://doi.org/10.1182/blood-2023-189286

Published: 2023

Journal Articles

CD70 CAR NK Cells in the Treatment of Multiple Myeloma

Paul Lin, Francia C. Reyes Silva, Pei Lin, April L. Gilbert, Sunil Acharya, Ana K. Nunez Cortes, Pinaki Banerjee, Dexing Fang, Luciana Melo Garcia, May Daher, MD, Rafet Basar, Krina K. Patel, Hans C. Lee, Robert Z. Orlowski, Hind Rafei, David Marin, Richard E. Champlin, Elizabeth J. Shpall, Katayoun Rezvani

Blood (2023) 142 (Supplement 1): 3463.

https://doi.org/10.1182/blood-2023-190612

Published: 2023

Journal Articles

Early Intervention and Favorable Biologic Effects of Personalized Neoantigen Vaccines on the Tumor Immune Microenvironment in Smoldering Waldenstrom Macroglobulinemia

Szymon Szymura, Soungchul Cha, Lin Wang, Tiantian Zhang, Zhenyuan Dong, Aaron Anderson, Elizabeth Oh, Zhe Wang, Vincent Lee, Sapna Parshottham, Sheetal Rao, Jasper B Olsem, Brandon N Crumpton, Hans C. Lee, Elisabet E. Manasanch, Sattva S. Neelapu, Sheeba K. Thomas, Larry W. Kwak

Blood (2023) 142 (Supplement 1): 212.

https://doi.org/10.1182/blood-2023-182448

Published: 2023

Journal Articles

Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience

Blood (2023) 142 (Supplement 1): 4963.

https://doi.org/10.1182/blood-2023-173697

Published: 2023

Journal Articles

Single Cell Multi-Omic Analysis of Neoplastic Plasma Cells across the Disease Spectrum Identifies Novel Pathobiologic Mediators and Potential Therapeutic Targets in Multiple Myeloma (MM)

Luz Yurany Moreno Rueda, Keiko Akagi, Amishi U. Vora, Hans C. Lee, Krina K. Patel, Pei Lin, Bo Jiang, Yang Song, Maura L. Gillison, Sheeba K. Thomas, Donna M. Weber, Lixia Diao, Jing Wang, Elisabet E. Manasanch, David E. Symer, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 752.

https://doi.org/10.1182/blood-2023-188016

Published: 2023

Journal Articles

Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in -Class Transition ( i CT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma

Hans C. Lee, June Li, Heather Lin, Astrid D. Murga, Gabriela M Rodriguez, Mostafa E. Mohamed, Jared Henderson, Sarah Rodriguez, Melody R. Becnel, Donna M. Weber, Swami P. Iyer, Gregory P. Kaufman, Sheeba K. Thomas, Elisabet E. Manasanch, Krina K. Patel, Stephen J. Noga, Michael R. Green, Robert Z. Orlowski, Cara L Haymaker

Blood (2023) 142 (Supplement 1): 4760.

https://doi.org/10.1182/blood-2023-188201

Published: 2023

Journal Articles

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Blood (2023) 142 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2023-177968

Published: 2023

Journal Articles

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 7070.

https://doi.org/10.1182/blood-2023-189109

Published: 2023

Journal Articles

Caseinolytic Mitochondrial Matrix Peptidase Proteolytic Subunit (CLPP) As a Novel Mediator of, and Target in High Risk Multiple Myeloma

Li Qin, Luz Yurany Moreno Rueda, Iqbal Mahmud, Isere Kuiatse, Wei Tan, Hans C. Lee, Krina K. Patel, David E. Symer, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 3302.

https://doi.org/10.1182/blood-2023-190766

Published: 2023

Journal Articles

Clinical Outcomes in Real-World Patients (RW) with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): A Retrospective Study Using Electronic Health Records from Flatiron Health and COTA Vantage Databases

Hans C. Lee, Sundar Jagannath, Devender Dhanda, Teofilia Acheampong, Pallavi Patwardhan, Thomas S. Marshall, Suvina Amin, Tao Gu, Sikander Ailawadhi

Blood (2023) 142 (Supplement 1): 3775.

https://doi.org/10.1182/blood-2023-173661

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Blood (2023) 142 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2023-179170

Published: 2023

Journal Articles

The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients

Blood (2023) 142 (Supplement 1): 4784.

https://doi.org/10.1182/blood-2023-188115

Published: 2023

Journal Articles

Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4972.

https://doi.org/10.1182/blood-2023-189844

Published: 2023

Journal Articles

Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2023-174558

Published: 2023

Journal Articles

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Hans C. Lee, Rafat Abonour, Sikander Ailawadhi, Brian G.M. Durie, Cristina J. Gasparetto, James W. Hardin, Mohit Narang, James Omel, Robert M. Rifkin, Howard Terebelo, Kathleen Toomey, Lynne I. Wagner, Samantha Slaff, Dailan Danforth, Weiyuan Chung, Jasmeet Anand, Edward Yu, Derek Tang, Sundar Jagannath

Blood (2022) 140 (Supplement 1): 13256–13258.

https://doi.org/10.1182/blood-2022-158197

Published: 2022

NARROW

Attrition after Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Products in Multiple Myeloma (MM)

Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation

Single Cell Multi-Omic Analysis of Tumor Microenvironment Evolution across the Disease Spectrum of Multiple Myeloma Identifies Differential Mechanisms of Immune Suppression

Safety and Efficacy Outcomes for Patients with High-Risk Multiple Myeloma Receiving Idecabtagene Vicleucel: The MD Anderson Experience

Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center

Lysosomal Associated Membrane Protein Family Member 5 (LAMP5) As a Novel Mediator of, and Target in High Risk Multiple Myeloma (MM)

CD70 CAR NK Cells in the Treatment of Multiple Myeloma

Early Intervention and Favorable Biologic Effects of Personalized Neoantigen Vaccines on the Tumor Immune Microenvironment in Smoldering Waldenstrom Macroglobulinemia

Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience

Single Cell Multi-Omic Analysis of Neoplastic Plasma Cells across the Disease Spectrum Identifies Novel Pathobiologic Mediators and Potential Therapeutic Targets in Multiple Myeloma (MM)

Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in -Class Transition ( i CT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation

Caseinolytic Mitochondrial Matrix Peptidase Proteolytic Subunit (CLPP) As a Novel Mediator of, and Target in High Risk Multiple Myeloma

Clinical Outcomes in Real-World Patients (RW) with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): A Retrospective Study Using Electronic Health Records from Flatiron Health and COTA Vantage Databases

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients

Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only